Our Startups
Enterprise Innovation has launched a diverse portfolio of companies that are based on foundational intellectual property developed in the research laboratories of Weill Cornell Medicine. Our current portfolio of companies encompasses key health care verticals including diagnostics, digital health, therapeutics, medical devices and R&D products and services.
Weill Cornell Medicine Startups
XenImmune Therapeutics, Inc.
XenImmune Therapeutics is developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection.
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. XyloCor's lead product candidate, XC001, is in clinical development for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, for patients with cardiac tissue damage from heart attacks.